Under 10% of people that would benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it issues its inaugural guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be treated with holistic and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major barriers to broad access to the injections that can aid individuals in losing considerable weight, notes the organization.
GLP-1 Therapy Supply Crisis
Even under the current most optimistic case, the production of these medications would only suffice for about 100 million people – under 10% of those who need them, according to the health organization.
The recommendation urges countries and companies to widen access, by approaches such as patent sharing.
A patent on the active ingredient – the core component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and enhance the sense of being full so people consume fewer calories.
Patients typically begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies points to people may see weight return within a year of halting the drug, as their typical appetite come back.
Being carrying excess weight raises your chance for developing medical conditions, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
